asthma

News

GSK scores a first approval in the UK for new severe asthma and CRSwNP therapy Exdensur, but a second in the US covers the asthma indication only.

News

GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.

News

AstraZeneca and Organon have breached the UK pharma industry's code of practice with promotions for an asthma drug and a contraceptive implant.

News

AstraZeneca's three-drug inhaler Breztri has shown efficacy for uncontrolled asthma in a pair of trials that could extend its label beyond COPD.

News

Sanofi is preparing a phase 3 programme for asthma candidate amlitelimab, despite mixed data in a phase 2 trial.

News

Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.